Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 15;16(10):5326-5336.
doi: 10.62347/HJVG8103. eCollection 2024.

Effect of QingreHuoxue formula on Th17 cells and Tregs in mice with idiopathic membranous nephropathy

Affiliations

Effect of QingreHuoxue formula on Th17 cells and Tregs in mice with idiopathic membranous nephropathy

Chengli Lou et al. Am J Transl Res. .

Abstract

Objectives: This study aimed to evaluate the therapeutic effect of the QingreHuoxue formula on mice with Idiopathic Membranous Nephropathy (IMN) and its impact on Th17 cells and Tregs.

Methods: A mouse model of IMN was established, and the mice were treated with traditional Chinese medicine, western medicine, or a combination of both. The efficacy and immunomodulatory effects of the QingreHuoxue formula were evaluated by examining renal pathology, urinary protein levels, peripheral blood Th17 and Treg cell counts, and comparing the expression levels of IL-17 and transforming growth factor-β1 in renal tissues.

Results: Compared to the untreated IMN model group, the IMN mice treated with TCM, western medicine, or the combination showed significant improvements in proteinuria, renal pathology, peripheral T lymphocyte counts, and IL-17 expression in renal tissues. Notably, the group treated with a combination of Chinese and western medicine exhibited better outcomes than the group treated with western medicine alone.

Conclusions: The QingreHuoxue formula was effective in reducing proteinuria, modulating T cell immune function, and protecting renal tissue in mice with IMN.

Keywords: QingreHuoxue formula; idiopathic membranous nephropathy.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Protocol of animal experiments.
Figure 2
Figure 2
Urine protein at baseline and 16-hours. A. Urine protein test dipsticks on day 1 of treatment; B. 16-hour urinary protein volume (mg). *P < 0.05 C, W, C+W vs. IMN. Western Medicine (W), Traditional Chinese Medicine plus Western Medicine (C+W), idiopathic membranous nephropathy (IMN).
Figure 3
Figure 3
H&E and PAS staining results.
Figure 4
Figure 4
Immunofluorescence staining. (A) Sham group, (B) IMN group, (C) C group, (D) W group, (E) C+W group, (F) Fluorescence intensity (n=10). *P < 0.05 vs. IMN group. Western Medicine (W), Traditional Chinese Medicine plus Western Medicine (C+W), idiopathic membranous nephropathy (IMN).
Figure 5
Figure 5
Renal specimens under transmission electron microscope. (A) Sham group, (B) IMN group: BGM thickening + immune complex protrusion, (C) C group: a small number of immune complexes protrude below the epithelium, (D) W group: a small number of immune complexes protrude below the epithelium, (E) C+W group: a small number of immune complexes protrude below the epithelium. Western Medicine (W), Traditional Chinese Medicine plus Western Medicine (C+W), idiopathic membranous nephropathy (IMN).
Figure 6
Figure 6
Flow cytometry results. A. The proportion of Th17 cells in peripheral blood. B. The proportion of Treg in peripheral blood. C. Relative cell proportion of Th17 cells and Treg. *P < 0.05 vs. IMN group. Western Medicine (W), Traditional Chinese Medicine plus Western Medicine (C+W), idiopathic membranous nephropathy (IMN).
Figure 7
Figure 7
Expression of IL-17 and TGF-β1 in renal specimens. A. Immunohistochemical staining of IL-17 and TGF-β1. B. Results of immunoblotting. C. Results of q-PCR. *P < 0.05 vs. IMN group. Western Medicine (W), Traditional Chinese Medicine plus Western Medicine (C+W), idiopathic membranous nephropathy (IMN).

Similar articles

References

    1. Zou H, Jiang F, Xu G. Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy. Ren Fail. 2019;41:673–681. - PMC - PubMed
    1. Hofstra JM, Wetzels JF. Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands. Nephrol Dial Transplant. 2008;23:3534–3538. - PubMed
    1. Liu D, Yang Y, Kuang F, Qing S, Hu B, Yu X. Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: a pairwise and network meta-analysis. Int Immunopharmacol. 2019;70:354–361. - PubMed
    1. Liu J, Li X, Huang T, Xu G. Efficacy and safety of 12 immunosuppressive agents for idiopathic membranous nephropathy in adults: a pairwise and network meta-analysis. Front Pharmacol. 2022;13:917532. - PMC - PubMed
    1. Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12:983–997. - PMC - PubMed

LinkOut - more resources